{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:50:48Z","timestamp":1780638648622,"version":"3.54.1"},"reference-count":58,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,6,10]]},"DOI":"10.18632\/oncotarget.3920","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T06:31:06Z","timestamp":1442298666000},"page":"13962-13977","source":"Crossref","is-referenced-by-count":53,"title":["AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1\/4E-BP1 axis"],"prefix":"10.18632","volume":"6","author":[{"given":"Wenting","family":"Mi","sequence":"first","affiliation":[{"name":"Markey Cancer Center and Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA"},{"name":"Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ye","sequence":"additional","affiliation":[{"name":"Markey Cancer Center and Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Side","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Bai","family":"She","sequence":"additional","affiliation":[{"name":"Markey Cancer Center and Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,4,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Sawyers","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","article-title":"PTEN and the PI3-kinase pathway in cancer","volume":"4","author":"Baker","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Sabatini","year":"2012","journal-title":"Cell"},{"key":"5","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1101\/gad.912401","article-title":"Hierarchical phosphorylation of the translation inhibitor 4E-BP1","volume":"15","author":"Sonenberg","year":"2001","journal-title":"Genes Dev"},{"key":"6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"Hinnebusch","year":"2009","journal-title":"Cell"},{"key":"7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc2824","article-title":"Translational control in cancer","volume":"10","author":"Schneider","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Martin","year":"2012","journal-title":"Nature"},{"key":"9","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/onc.2013.122","article-title":"ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer","volume":"33","author":"She","year":"2014","journal-title":"Oncogene"},{"key":"10","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.18632\/oncotarget.2109","article-title":"Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail","volume":"5","author":"She","year":"2014","journal-title":"Oncotarget"},{"key":"11","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1158\/0008-5472.CAN-07-0881","article-title":"4E-binding protein 1: a key molecular \u201cfunnel factor\u201d in human cancer with clinical implications","volume":"67","author":"Ramon y Cajal","year":"2007","journal-title":"Cancer Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccr.2010.05.023","article-title":"4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors","volume":"18","author":"Rosen","year":"2010","journal-title":"Cancer Cell"},{"key":"13","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/onc.2013.92","article-title":"Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors","volume":"33","author":"Warren","year":"2014","journal-title":"Oncogene"},{"key":"14","first-page":"e331","article-title":"New insights into 4E-BP1-regulated translation in cancer progression and metastasis","volume":"1","author":"She","year":"2014","journal-title":"Cancer Cell Microenviron"},{"key":"15","doi-asserted-by":"crossref","first-page":"10189","DOI":"10.1074\/jbc.M210837200","article-title":"Identification of a proline-rich Akt substrate as a 14-3-3 binding partner","volume":"278","author":"Roth","year":"2003","journal-title":"J Biol Chem"},{"key":"16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase","volume":"25","author":"Sabatini","year":"2007","journal-title":"Mol Cell"},{"key":"17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ncb1547","article-title":"Insulin signalling to mTOR mediated by the Akt\/PKB substrate PRAS40","volume":"9","author":"Kim","year":"2007","journal-title":"Nat Cell Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"20329","DOI":"10.1074\/jbc.M702636200","article-title":"The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1","volume":"282","author":"Yonezawa","year":"2007","journal-title":"J Biol Chem"},{"key":"19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-009-0004-4","article-title":"Activation of PI3K\/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival","volume":"97","author":"Haas-Kogan","year":"2010","journal-title":"J Neurooncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"E1453","DOI":"10.1152\/ajpendo.00660.2011","article-title":"Role of PRAS40 in Akt and mTOR signaling in health and disease","volume":"302","author":"Ouwens","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"21","first-page":"149","article-title":"Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer","volume":"10","author":"Wu","year":"2014","journal-title":"Arch Med Sci"},{"key":"22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Hall","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.bbapap.2013.01.041","article-title":"Overcoming resistance to rapalogs in gliomas by combinatory therapies","volume":"1834","author":"Hemmings","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"24","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Khuri","year":"2005","journal-title":"Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"Rosen","year":"2006","journal-title":"Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"e3065","DOI":"10.1371\/journal.pone.0003065","article-title":"Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling","volume":"3","author":"Rosen","year":"2008","journal-title":"PLoS ONE"},{"key":"27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2010.01.021","article-title":"Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E","volume":"17","author":"Ruggero","year":"2010","journal-title":"Cancer Cell"},{"key":"28","doi-asserted-by":"crossref","first-page":"E699","DOI":"10.1073\/pnas.1108237108","article-title":"PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis","volume":"108","author":"Roberts","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1242\/jcs.137588","article-title":"Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation","volume":"127","author":"Cook","year":"2014","journal-title":"J Cell Sci"},{"key":"30","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors","volume":"29","author":"Heaton","year":"2011","journal-title":"J Clin Oncol"},{"key":"31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2159-8290.CD-11-0170","article-title":"Genomic complexity and AKT dependence in serous ovarian cancer","volume":"2","author":"Stanchina","year":"2012","journal-title":"Cancer Discov"},{"key":"32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature11163","article-title":"mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake","volume":"486","author":"Zukerberg","year":"2012","journal-title":"Nature"},{"key":"33","doi-asserted-by":"crossref","first-page":"E1382","DOI":"10.1073\/pnas.1418973112","article-title":"Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17beta is mediated by a PKC-ERK1\/2-mTOR signaling pathway","volume":"112","author":"Pollard","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"34","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-11-3321","article-title":"Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma","volume":"18","author":"Thiele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1158\/1078-0432.CCR-11-1407","article-title":"Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma","volume":"18","author":"Parekh","year":"2012","journal-title":"Clin Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1158\/0008-5472.CAN-12-0283","article-title":"Dual targeting of the Akt\/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model","volume":"72","author":"Abate-Shen","year":"2012","journal-title":"Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1158\/1535-7163.MCT-13-0159","article-title":"Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models","volume":"12","author":"Ma","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"38","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1158\/0008-5472.CAN-08-1522","article-title":"Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR\/raptor inhibition-initiated, mTOR\/rictor-independent Akt activation","volume":"68","author":"Sun","year":"2008","journal-title":"Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1126\/science.1187532","article-title":"mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs","volume":"328","author":"Sonenberg","year":"2010","journal-title":"Science"},{"key":"40","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1097-2765(03)00395-2","article-title":"Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes","volume":"12","author":"Holland","year":"2003","journal-title":"Mol Cell"},{"key":"41","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Blenis","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"42","doi-asserted-by":"crossref","first-page":"1236566","DOI":"10.1126\/science.1236566","article-title":"mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin","volume":"341","author":"Sabatini","year":"2013","journal-title":"Science"},{"key":"43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sabatini","year":"2006","journal-title":"Mol Cell"},{"key":"44","doi-asserted-by":"crossref","first-page":"e1214","DOI":"10.1038\/cddis.2014.178","article-title":"Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium","volume":"5","author":"Blagosklonny","year":"2014","journal-title":"Cell Death Dis"},{"key":"45","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sabatini","year":"2005","journal-title":"Science"},{"key":"46","first-page":"e38","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Shokat","year":"2009","journal-title":"PLoS Biol"},{"key":"47","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Gray","year":"2009","journal-title":"J Biol Chem"},{"key":"48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rosen","year":"2011","journal-title":"Cancer Discov"},{"key":"49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4161\/cc.11.3.19096","article-title":"mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors","volume":"11","author":"Zheng","year":"2012","journal-title":"Cell Cycle"},{"key":"50","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccr.2006.03.029","article-title":"A dual PI3 kinase\/mTOR inhibitor reveals emergent efficacy in glioma","volume":"9","author":"Weiss","year":"2006","journal-title":"Cancer Cell"},{"key":"51","doi-asserted-by":"crossref","first-page":"22299","DOI":"10.1073\/pnas.0905152106","article-title":"Specific apoptosis induction by the dual PI3K\/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells","volume":"106","author":"Maira","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"52","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Parra","year":"2008","journal-title":"Cancer Res"},{"key":"53","doi-asserted-by":"crossref","first-page":"e25132","DOI":"10.1371\/journal.pone.0025132","article-title":"The dual PI3K\/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer","volume":"6","author":"Hung","year":"2011","journal-title":"PLoS ONE"},{"key":"54","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1158\/0008-5472.CAN-10-4322","article-title":"Combination of PI3K\/mTOR inhibitors: antitumor activity and molecular correlates","volume":"71","author":"Broggini","year":"2011","journal-title":"Cancer Res"},{"key":"55","first-page":"196ra199","article-title":"mTORC1 Inhibition Is Required for Sensitivity to PI3K p110alpha Inhibitors in PIK3CA-Mutant Breast Cancer","volume":"5","author":"Hazra","year":"2013","journal-title":"Sci Transl Med"},{"key":"56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/jid.2010.327","article-title":"Vertical inhibition of the mTORC1\/mTORC2\/PI3K pathway shows synergistic effects against melanomaand","volume":"131","author":"Wacheck","year":"2011","journal-title":"J Invest Dermatol"},{"key":"57","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cyto.990110707","article-title":"Flow cytometric analysis of G1- and G2\/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements","volume":"11","author":"Tarnok","year":"1990","journal-title":"Cytometry"},{"key":"58","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/371762a0","article-title":"Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5\u2032-cap function","volume":"371","author":"Sonenberg","year":"1994","journal-title":"Nature"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T21:06:39Z","timestamp":1653167199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,23]]},"references-count":58,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015,6,10]]}},"alternative-id":["3920","25961827"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3920","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,23]]}}}